Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient’s regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.

• Revenue in USD (TTM)1.46m
• Net income in USD-53.12m
• Incorporated2018
• Employees12.00

• Location
  Onconetix Inc201 E. Fifth Street, Suite 1900CINCINNATI 45202United StatesUSA
• Phone+1 (513) 620-4101
• Fax+1 (845) 818-3588
• Websitehttps://onconetix.gcs-web.com/